Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem
Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem